Course handouts are now available
Click here
Come to London
WATCH to find out why
Site updates:
Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.
Posters
(results will display both Free Papers & Poster)
Keratoconus in children: management and clinical outcome at 2 year follow-up
Poster Details
First Author: C.Ciocanea FRANCE
Co Author(s): F. Ernould T. Randon J. Rouland
Abstract Details
Purpose:
Assess particularities in decision making and outcomes in Keratoconus in children and adolescents.
Setting:
Department of Ophthalmology, Lille University Hospital, France
Methods:
46 eyes from 23 children and adolescents (aged 12 to 18 years) with confirmed Keratoconus were included in this retrospective study between January 2011 and December 2012. Refraction, best corrected visual acuity (BCVA), slit-lamp examination and corneal video-topography were performed bilaterally. Management strategy included: corneal cross-linking, lens fitting, corneal grafting or intracorneal ring segments. Maximal keratometry and BCVA were analyzed to study efficiency of corneal cross-linking.
Results:
According to Krumeich classification, the severity of Keratoconus at diagnosis was: stage 1 in 14 (30, 4%) eyes, stage 2 in 21 (45.6%) eyes, stage 3 in 3 (6, 52%) eyes and stage 4 in 8 (17.3%) eyes. 50% of eyes had progression of Keratoconus. 19 eyes underwent corneal cross-linking early after diagnosis with a mean delay between diagnosis and treatment of 7, 84 months (1 to 20 months). Flattening of maximum keratometry in treated eyes was significant (p<0.001) at 1 year follow-up. BCVA increased after corneal cross-linking of 0, 1 logMar in 6 (31%) of the treated eyes. No severe complication was recorded. Rigid gas-permeable lenses were successfully fitted in 17(36%) eyes with significant improvement of visual acuity.
Conclusions:
Keratoconus in children has a scalable presentation at diagnosis and rapid progression. Corneal cross-linking should not be delayed in these patients were treatment shows safety and efficiency at follow-up. FINANCIAL INTEREST: NONE